VM-GD / Boryung Group - LARVOL DELTA

Vigencell, VM-GD Phase 1/2a Clinical Trial Ended Early to Apply New Manufacturing Process [Google translation] (Pharm News) - "Plans to re-apply for clinical trial plan (IND) using the new process and expand indications in the future....Vigencell...announced on the 28th that it has terminated the domestic phase 1/2a clinical trial of 'VM-GD' early in order to apply a new manufacturing process that enables cost reduction with higher production efficiency than the existing process....ViMedier's 'VM-GD...is a pipeline under development with graft-versus-host disease (GvHD) as an indication....'we will do our best to reapply for the clinical trial as soon as possible so that we can provide a good treatment option for patients with graft-versus-host disease.'"

Trial suspension • Graft versus Host Disease

Kim Tae-gyu, CEO of Vigencell “Starts clinical trial for autoimmune disease ‘VM-GD’ next year” [Google translation] (eDaily) - “We plan to start phase 1/2a clinical trials next year for graft-versus-host disease candidates using the cell therapy platform 'Bymedia' that can be produced universally. With the clinical launch of the third immunotherapeutic drug that the company discovered on its own, the process for producing its own clinical samples will also be established within the year....'There are aspects of the VM-GD clinical trial being delayed due to issues such as manufacturing issues and indications with a small number of patients.'"

New P1/2 trial • Graft versus Host Disease • Immunology